Summit Therapeutics, Inc. is a pharmaceutical company in the United States that specializes in developing novel antibiotics for infectious diseases. With an ESG score indicating medium risk, Summit Therapeutics focuses on creating sustainable solutions for healthcare. Their CDI product candidate, ridinilazole, is a small molecule antibiotic for Clostridiodes difficile infection. Operating in both the US and the UK, Summit Therapeutics is dedicated to promoting environmental sustainability and good corporate governance.